HIV causes several forms of immune dysfunction that need to be addressed in a functional cure for HIV. Immune exhaustion describes a dysfunctional phenotype caused by chronic cellular activation. Lymphocyte activation gene-3 (LAG3) is one of several negative coreceptors known as immune checkpoints that contribute to this exhaustion phenotype. Antibodies targeting immune checkpoints are now used clinically to restore immunity against cancer and hold promise in restoring immunity during HIV infection. Here, we summarize current knowledge surrounding LAG3 and discuss its relevance during HIV infection and the potential for LAG3-targeting antibodies in a functional HIV cure.
Antiviral drugs have transformed HIV infection from a death sentence to a manageable disease. However, millions still lack access to these drugs, which require daily adherence. This allows the HIV epidemic to continue, killing a million people each year. The search for a cure has been long, but researchers now have a greater knowledge of HIV and human biology than ever before and are designing drugs and strategies that may be used in a cure. Checkpoint blockade is one strategy already used to treat cancer but may also eventually be used in an HIV functional cure, which would allow the body to control HIV without the help of antiviral drugs. Checkpoint blockade works by inhibiting molecules called immune checkpoints, which are the brakes of the immune system. Here we focus on an immune checkpoint called LAG3. LAG3 can be present on many different immune cells with differing frequency but is more abundant during HIV, in which having more LAG3 is associated with certain aspects of worse disease. Although it may have slightly different functions on different types of cells, overall, LAG3 reduces the cell’s ability to respond to stimulus. Inhibiting LAG3 could reinvigorate immune cells to fight HIV and may even help fight coinfections such as hepatitis viruses. Inhibiting other immune checkpoints along with LAG3 may improve efficacy. If combined with other drugs and strategies to fight HIV, checkpoint blockade may allow the immune system to control HIV without the help of antiviral drugs—a functional cure.
Citation: Graydon CG, Balasko AL, Fowke KR (2019) Roles, function and relevance of LAG3 in HIV infection. PLoS Pathog 15(1): e1007429. https://doi.org/10.1371/journal.ppat.1007429
Editor: Tom C. Hobman, University of Alberta, CANADA
Published: January 17, 2019
Copyright: © 2019 Graydon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a CIHR grant (3192983410002000) and by The Canadian HIV Cure Enterprise Team Grant HIG-133050 (to KRF) from the CIHR in partnership with CANFAR and IAS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Antiretroviral therapy (ART) inhibits human immunodeficiency virus (HIV) replication, but a reservoir of latently infected cells means that ART must be taken indefinitely and thus does not constitute a cure. The ideal HIV cure would completely eradicate HIV. However, a functional cure, in which HIV is permanently suppressed in latent reservoirs, is more feasible with lower cost and less severe side effects. Restorative immunotherapy may help achieve a functional cure by reversing the immune exhaustion during HIV infection.
Immune exhaustion describes a phenotype of misplaced tolerance coinciding with expression of inhibitory proteins, known as immune checkpoints (IC) (e.g., lymphocyte activation gene-3 [LAG3], programmed cell death-1 [PD1], TIM3 [T-cell immunoglobulin and mucin-domain containing-3], TIGIT [T-cell immunoreceptor with Ig and ITIM domains], CTLA-4 [cytotoxic T-lymphocyte-associated protein-4], BTLA [B- and T-lymphocyte attenuator], 2B4), that impair cellular immune response. Like other ICs, LAG3 likely evolved as an immuno-regulatory strategy to protect from organ damage during aberrant or excessive immune activation (e.g., allergy, autoimmunity, inflammatory bowel disease)[1–4]; however, when a strong immune response is desired, misplaced LAG3-mediated immunosuppression may be detrimental. Immune exhaustion harms are evident in cancer, in which antibodies blocking PD1 and CTLA-4 substantially increase survival and have become first-line treatment for advanced melanoma . Indeed, the 2018 Nobel Prize in Physiology or Medicine was awarded to pioneers of this research . Although ICs may seem redundant, their differing expression patterns and signaling mechanisms, and their functional synergy provide the opportunity to take advantage of functional redundancies to more accurately target and titrate immune restoration. For HIV, reversing immune exhaustion may restore immunity, thereby reducing opportunistic infection and improving control of HIV. Here, we review LAG3, its relevance in HIV infection, and its therapeutic potential within a functional cure.
LAG3, a member of the immunoglobulin superfamily, is expressed on T cells, natural killer (NK) cells, plasmacytoid dendritic cells (pDCs) and B cells. LAG3 is frequently studied on T-cells, in which it translocates to lipid rafts on the cell surface after cellular activation, forming dimers and oligomers which colocalize with cluster of differentiation 3 [CD3] and CD4/CD8 upon reactivation [7–9]. T-cells LAG3-expression generally increases with differentiation [10–12].
The lymphocytic choriomeningitis virus (LCMV) infection mouse model is useful for studying LAG3 in vivo because acute and chronic strains exist. After 1 to 2 weeks of LCMV infection, LAG3 expression peaks on T-cells. In the acute model, virus is cleared and LAG3 expression decreases, allowing activated cells to differentiate into memory cells. In the chronic model, LAG3 remains elevated, representing exhaustion [13,14]. Then, like other ICs, LAG3 is elevated during HIV, cancer, tuberculosis, and hepatitis B and C [11,15–22]. This up-regulation is driven on T-cells by T-cell receptor (TCR) stimulation and on activated NK and T-cells by interleukin 12 [IL-12] in an interferon-γ [IFNγ]-dependent manner [23,24]. Other cytokines, such as IL-27, IL-15, IL-2, and IL-7, also up-regulate LAG3 [1,23–27]. LAG3 may also regulate and be regulated by T-bet (a T-box transcription factor), which along with Eomesodermin, guides differentiation of cytotoxic T lymphocytes (CTLs). Indeed, deletion of T-bet increases LAG3 expression on murine T-cells, and in turn LAG3 knockout increases T-bet [28,29]. HIV-specific CTLs are overwhelmingly T-betdim, even following ART-initiation.
Although TCR stimulation and cytokines up-regulate LAG3, toll-like receptor (TLR) stimulation may oppose this, at least in mice, potentially by increasing expression and activity of transmembrane matrix metalloproteases A disintegrin and metalloproteinase domain-containing protein 10 [ADAM10] and ADAM17 , which regulate LAG3 through membrane cleavage , or by increasing T-bet activity . During HIV infection, LAG3 remains elevated despite presence of TLR ligands. ART may reduce LAG3 on bulk T-cells but not on central memory T-cells, NKs, or invariant-NK T-cells (iNKTs) [10,11,15]. Whether this regulation of LAG3 is appropriate during HIV infection is unclear. However, PD1 blockade successes in HIV, discussed later, indicate that ICs are overexpressed .
Discovered in 1990, LAG3 was recognized to share ancestral homology and structural similarity to CD4 . LAG3 regulates T-cell activation mainly through interaction with major histocompatibility complex (MHC) class II, binding with 100-fold the affinity of CD4 [35–38]. Unlike CD4, however, LAG3 does not bind the HIV envelope glycoprotein 120 [gp120], so it is thought not to be an HIV receptor . However, as Human Leukocyte Antigen-DR (HLA-DR), an MHC-II molecule, is expressed on activated T-cells, both LAG3 and its main receptor are elevated during HIV infection, perhaps enhancing immunosuppression.
In mice, LAG3 also binds two lectins, Galectin-3 (Gal3) and liver and lymph node sinusoidal endothelial cell C-type lectin (LSECtin), in both cases suppressing CTL IFNγ production [39,40]. HIV and its trans-activator of transcription (Tat) protein up-regulate Gal3, which also enhances HIV budding and transfer [41,42]. Gal3 exists intracellularly and extracellularly with distinct functions and binds to many glycosylated proteins with diverse physiological outcomes . In comparison, LSECtin is lesser known and participates in antigen recognition, uptake, and internalization . Any evolutionary reason for the interaction between these lectins and LAG3 is unclear but likely dependent on the heavy glycosylation of LAG3. Research is needed to confirm LAG3–lectin interaction in humans to determine the importance of Gal3 and LSECtin.
LAG3 differs from other ICs because it lacks noticeable inhibitory motifs. Early studies of LAG3’s mechanism supported the idea that LAG3 inhibited T-cell activation through competition with CD4—just as CTLA-4 competes with CD28 for CD80/86 , by demonstrating that LAG3 inhibited IL-2 production of a CD4+ T-cell hybridoma but not of a CD4− variant—and that this inhibition depended on MHC-II . However, this same study showed that mutating a lysine residue in the cytoplasmic domain abolished LAG3 function, implying an intracellular mechanism rather than receptor competition. This is further supported by evidence that LAG3 inhibits CTLs (discussed below), has non-MHC-II ligands , binds a different site of MHC-II than CD4, and does not competitively inhibit CD4 during TCR ligation . A potential explanation for this apparent paradox is that LAG3 inhibits intracellular signaling proteins dependent on CD4 or CD8, such as lymphocyte-specific protein tyrosine kinase (Lck). Details of LAG3’s intracellular mechanism remain uncharacterized except that LAG3 inhibits calcium flux and nuclear factor of activated T-cells (NFAT) activation during TCR stimulation [47,48]. Although a LAG3-associated protein binds the glutamine proline (EP) motif of LAG3’s intracellular domain, deletion of this motif did not abrogate LAG3’s function [46,49]. Research of LAG3’s role and mechanism has largely been restricted to inhibition of TCR-dependent stimulation and its interaction with MHC-II. However, the antibody typically used to inhibit murine LAG3 (clone C9B7W) does not block the LAG3 MHC-II interaction . Furthermore, LAG3 maintains its role on non–T-cells, as discussed below. Therefore, LAG3 may also function in TCR-independent stimulations such as through cytokine or pattern recognition receptors. Therefore, more research into the LAG3 mechanism and situational roles is critical.
LAG3 function on cell types and subsets
LAG3 on conventional T-cells
T-cell exhaustion is generally viewed as CTL dysfunction, but CD4+ T-cell exhaustion also exists . Although cell-line studies show that LAG3 inhibits CD4+ T-cell function [11,46,47], differential function of LAG3 between these cells and CTLs remains largely uninvestigated. Although one study found no effect of LAG3-blockade on CTL activation  and another study demonstrated that inhibition of CTL function is dependent on CD4+ T-cell LAG3 expression, others show that LAG3 inhibits CTL independently of CD4+ T-cells [22,54]. Overall, studies suggest LAG3 regulates the CTL response but may have greater impact when expressed on CD4+ T-cells. LAG3-inhibition of CTLs is curious because MHC-II, which CTLs do not recognize, is the main receptor for LAG3. We propose several possible mechanisms for this curiosity (Fig 1). Although LAG3-mediated regulation protects T-cells from activation-induced cell death following intense stimulation, LAG3 offers no protection from apoptosis following physiologically relevant stimulation [7,14,55].
HIV induces inflammation and immune activation, which leads to exhausted lymphocytes and increased expression of LAG3 and HLA-DR, an HLA class II molecule. LAG3 may inhibit CTL activation by binding to (1) the alternative LAG3 ligands LSECtin or Gal3, (2) HLA class II molecules that traffic to the immune synapse on the target cell or (3) HLA class II molecules that traffic to the immune synapse on the same cell, or by (4) cotrafficking with CD8 to the immune synapse, which occurs during CD8 crosslinking . Productive HIV infection increases production of Gal3, which can inhibit CTL activation and killing. Productive infection can be induced from latent infection through activation of certain transcription factors, including NFAT, which is inhibited by LAG3 during T-cell activation. CD, cluster of differentiation; CTL, cytotoxic T lymphocytes; Gal3, Galectin-3; HLA, human leukocyte antigen; LAG3, lymphocyte activation gene-3; LSECtin, liver and lymph node sinusoidal endothelial cell C-type lectin; NFAT, nuclear factor of activated T-cells; TCR, T-cell receptor.
LAG3 on T regulatory cells
Whether T regulatory cells (Tregs) are beneficial or detrimental in HIV pathogenesis is unclear. As previously reviewed, Tregs abate HIV-related inflammation but also suppress desired anti-HIV immunity [56–58]. Likewise, Treg LAG3 expression is higher than for conventional T-cells [59,60]; its role on Tregs remains controversial. Early studies suggested LAG3 enhances Treg function when the inflammatory and/or antigenic burden is high [1,59] but not in less demanding environments [53,59,61], in which LAG3 expressed on the responding T-cell had greater impact [29,53]. In contrast, studies using similar models show LAG3 inhibiting Treg function and impairing Treg development [29,62,63]. One consistent finding throughout these studies is that LAG3 inhibits proliferation of Tregs. The literature is similarly unclear on LAG3’s role in Treg inhibition of dendritic cell (DC) maturation, with studies showing conflicting results [60,64]. In summary, LAG3’s role on Tregs is not well defined but seems dependent on immune microenvironment.
LAG3 on plasmacytoid dendritic cells
As important producers of type I IFN and links between innate and adaptive immunity, pDCs play a significant role during HIV infection. However, like Tregs, the beneficial or detrimental effects of pDCs on HIV disease progression is debated. On one hand, pDCs may help control HIV by inhibiting viral replication and promoting CTL and NK cells through IFNα production and cross-presentation, especially during early infection . Yet, pDC-mediated immune activation may also contribute to immunopathology and immune exhaustion .
In mice, pDCs express 10-fold greater LAG3 than Treg and conventional T-cells . LAG3-expressing pDCs behave more tolerogenically than LAG3-negative pDCs—fewer IFNα, more IL-6, increased generation of Tregs, and induction of monocytes to recruit myeloid-derived suppressor cells . Furthermore, LAG3 on pDCs inhibits T-cell expansion and vice versa . These immunosuppressive and trans-cellular LAG3 effects may explain why LAG3 knockout mice have increased numbers of cell types that naturally lack LAG3—including granulocytes and macrophages —suggesting that LAG3 inhibits expansion of other innate immune cells by encouraging a suppressive environment.
LAG3 on NK and innate T-cells
LAG3 knockout mice have increased numbers of innate cells that would otherwise express LAG3, including γδT cells, NKs, and pDCs, implying that it regulates their expansion . LAG3 expression on innate cells—including mucosal-associated invariant T-cells (MAIT; 20%), NKs and iNKTs (1%–15%) [15,16], pDC (6%) , and γδT-cells (19% in mice) —is higher compared to conventional T-cells.
An early report showed LAG3-knockout or -blockade enhancing murine-NK killing of tumor cell lines ; however, a contrasting study was unable to confirm this in human NKs . Recently, two murine cancer models showed that LAG3-blockade after IL-12 administration reduced metastases and increased number and functionality of NKs, implying a similar regulatory role for LAG3 on NKs as on T-cells . Because LAG3 is up-regulated on NKs during HIV infection and is higher on those of HIV progressors compared to HIV controllers, this regulatory role represents a potential source of NK dysfunction during disease .
Our laboratory has shown LAG3 to be up-regulated on iNKTs during HIV infection [15,16]. iNKTs are innate-like cells, with both NK and T-cell markers, that respond to lipid antigens presented by the MHC-I–like molecule CD1d and are important linkers of the innate and adaptive immune system . Although beneficial for anti-HIV immunity, iNKTs are depleted and functionally impaired during HIV infection . We have previously shown that LAG3, but not PD1, expression on iNKTs in HIV-infected individuals is inversely correlated with their ability to produce IFNγ . Furthermore, LAG3 inhibits proliferation of iNKTs . Together, this indicates that LAG3 acts as an IC on iNKTs similarly to T-cells.
MAITs are an innate T-cell subset that comprise 1%–10% of peripheral T-cells but are exhausted and depleted from the periphery during HIV . Although their antiviral function is not clear, MAITs respond to bacterial metabolites and are likely important in defence against bacterial coinfections during HIV . Recently, it was discovered that LAG3 is highly up-regulated on MAITs following activation, causing functional impairment that is reversible with LAG3-blockade . MAIT LAG3 expression during HIV is unknown, but LAG3-blockade may partially reverse their dysfunction during disease.
Innate T-cells are more abundant in the gut and liver than peripheral blood. These are sites of intense inflammation during HIV infection, suggesting LAG3 expression in these areas may be even greater than in the blood. HIV can cause liver disease , in which iNKTs and MAITs comprise up to 30% and 50% of lymphocytes, respectively [78,79], and the LAG3 ligand LSECtin is highly expressed . During hepatitis B and C infections, LAG3 is up-regulated on T-cells, in which it reduces cytokine production and cytotoxicity but is uninvestigated on MAITs, NKs, and iNKTs [20–22]. Taken together, these studies indicate LAG3 is of great importance in the liver during HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) infection. Due to complex immune environments and severe immune-mediated liver damage often caused by these phasic infections, further study is needed to determine whether LAG3 is harmful or beneficial.
Overall, LAG3 is understudied on innate cells. This is especially true of γδT-cells. γδT-cells expressing Vδ2 are dysfunctional and severely depleted from peripheral blood during HIV infection . Although LAG3 expression on γδT-cells has been noted [35,82], little research has investigated its expression or function in these cells.
LAG3 and HIV disease
Immune exhaustion is a main facet of immune dysfunction and is associated with poor HIV disease outcomes. Indeed, LAG3 is associated with high viral load [11,19,83], faster disease progression , and rapid return of viraemia following treatment interruption . Moreover, LAG3 is down-regulated on NKs of HIV elite controllers—individuals with undetectable viral load despite being infected—and HIV-exposed seronegative (HESN) populations, and CD4+ T-cells of viraemic nonprogressors and elite controllers [16,84,85]. These studies do not resolve cause from effect, because LAG3 may represent immune activation rather than contribute to disease progression, but they demonstrate that LAG3 is associated with unfavourable disease measurements and could be a main contributor to immune exhaustion in HIV. Reversing immune exhaustion may restore immunity against coinfections and enhance HIV-specific immunity, making it a candidate for use in a functional cure.
LAG3-blockade: Potential in an HIV functional cure
The functional HIV cure goal is to suppress virus in latent reservoirs, eliminating the need for ART. Elite controllers demonstrate that such control is possible. A “shock and kill” tactic, in which “shock” refers to reactivation of HIV from latent reservoirs and “kill” denotes depletion of these now visibly infected cells, is one immune-based strategy for a functional cure. LAG3-blockade could be one component of this strategy by reversing latency and simultaneously enhancing HIV-specific immunity (Fig 1).
LAG3 and HIV latency
LAG3 is elevated in lymph nodes and tissues, areas in which the HIV reservoir is prominent . Because activation of NFAT and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) promotes HIV-transcription  and LAG3 inhibits NFAT and cellular activation, its blockade may reverse latency . Furthermore, memory T-cells expressing LAG3 alone, or coexpressing LAG3 with TIGIT and PD1, respectively, harbor 2-fold and 8-fold more integrated HIV DNA than their negative counterparts, implying an LAG3 or IC combination blockade would preferentially target infected cells . Although studies have not investigated whether LAG3 helps maintain HIV latency, studies have shown that PD1-blockade enhances latency reversal and exposes HIV in latently infected cells to the adaptive immune system for potential elimination [87–91].
Checkpoint blockade enhances HIV immunity
Strong immunity is critical to the “kill” aspect of the “shock and kill” tactic. Moreover, CTLs are necessary to maintain control of HIV . Reversing immune exhaustion could effectively restore this immunity. Indeed, only a short duration of LAG3-blockade enhances the formation of memory T-cells during viral infections [14,93].
Although LAG3 expression is not elevated on gag-responsive CTL compared to cytomegalovirus CMV-responsive counterparts, PD1 expression is [10,94]. As an approved first-line treatment for advanced melanoma, research into PD1-blockade is more developed than for LAG3-blockade. Although cells expressing abundant PD1 may be irreversibly exhausted, LAG3 is typically expressed without PD1 during HIV [11,12,95]. Furthermore, PD1-blockade improves frequency and response of HIV-specific CTL, and reduces viral load and mortality in simian immunodeficiency virus-infected macaques, indicating exhaustion in HIV is reversible [90,96]. Promising PD1-blockade studies in humanized mice  and ex vivo  have resulted in early clinical trial attempts to improve anti-HIV immunity. Thus far, case reports demonstrate increases in cell-associated HIV RNA and reductions in latent reservoir size after PD1/CTLA-4–blockade [89,98,99], and one clinical trial showed improved HIV-specific CTL responses in a subset of individuals taking PD-L1–blockade . However, retinal toxicity in a parallel macaque model study led to this human trial being stopped. This adverse event slowed IC-blockade research for HIV and warrants caution, although a recent similar study witnessed no side effects . It is unclear whether IC-blockade for HIV is any less safe than for cancer; however, HIV necessitates a different risk–benefit calculus for IC-blockade compared to cancer, with similar risk but lower benefit considering the alternative of lifelong ART. LAG3-blockade may be relatively safe because LAG3 knockout mice do not readily exhibit immunopathology, in contrast to PD1 and CTLA-4 deficient mice [101–103]. Indeed, preliminary trial results show LAG3+PD1 combination blockade has a similar safety profile to PD1 monotherapy in advanced melanoma patients . Furthermore, when PD1 is blocked, LAG3 and other ICs are often up-regulated in compensation and vice versa [62,105,106]. Therefore, although PD1-blockade is promising for HIV cure, other ICs or an IC combination blockade may improve safety or efficacy. Indeed, animal models of chronic viral infection and cancer have demonstrated that PD1+LAG3 combination blockade is more effective than either alone [107,108], and of the 33 ongoing registered clinical trials of LAG3-blockade, all but two are testing LAG3+PD1 combination blockade. Preliminary results of one such clinical trial demonstrates striking efficacy of LAG3+PD1-blockade (BMS-986016 and nivolumab, respectively) for treatment of advanced melanoma patients whom PD1/PD-L1-blockade previously failed (16% objective response rate and 45% disease control rate) .
Despite LAG3’s importance in cancer, allergy, autoimmunity, and infectious disease, much about its function is undefined. Although mechanisms and functions of LAG3 remain controversial, LAG3 clearly inhibits immune responses. Therefore, a main concern surrounding IC-blockade for HIV is that it may increase inflammation and immune activation, thereby accelerating disease. Although a valid concern, the preliminary successes of PD1-blockade support the argument that reversing immune exhaustion will result in favorable outcomes. Regardless, LAG3 and other IC-blockades should be investigated in HIV models with and without viral suppression to understand their roles during disease.
If LAG3-blockade improves immune function during HIV infection, it could help deplete the HIV reservoir by reversing latency and restoring immunity of exhausted cells. Providing ART is a priority; therefore checkpoint inhibition should be pursued for individuals with ART-suppressed virus. For untreated individuals, checkpoint blockade may increase cellular production of and susceptibility to HIV by enhancing immune activation. Furthermore, replicating HIV can evolve under selective pressure to evade CTL responses, an issue resolved by ART. However, few HIV antigens are exposed when HIV is suppressed. Therefore, during viral suppression, IC-blockades would likely be most effective when combined with triggers or other immunotherapies (Fig 2). Immunotherapies like IC-blockade have advantages, including almost no risk of HIV resistance and potentially improved broad immunity, particularly against coinfections. These advantages and the potential for a functional cure justify cautious optimism and further research of LAG3 expression, mechanism, and function.
A therapeutic vaccine (1) would enhance HIV-specific CTL number and function. Because many HIV-specific CTLs are exhausted during HIV, IC blockade could enhance the activating effect of the vaccine and the function of the CTL after activation. After administering this vaccine, checkpoint blockade could feasibly enhance LRAs (2) activity as previously demonstrated for PD1 . During LRA treatment, broadly neutralizing antibodies (3) could bind to HIV polypeptide expressed on the infected cell’s surface and activate antibody dependent cell cytotoxicity activity by NK cells, which may also be enhanced by checkpoint blockade . CD4, cluster of differentiation 4; CTL, cytotoxic T lymphocyte; HLA, human leukocyte antigen; IC, immune checkpoint; LRA, latency reversing agent; NK, natural killer; PD1, programmed cell death-1; TCR, T-cell receptor.
- 1. Do J-S, Visperas A, Sanogo YO, Bechtel JJ, Dvorina N, Kim S, et al. An IL-27/Lag3 axis enhances Foxp3(+) regulatory T cell-suppressive function and therapeutic efficacy. Mucosal Immunol. 2015 May 27;9(1):137–45. pmid:26013006
- 2. Burton BR, Britton GJ, Fang H, Verhagen J, Smithers B, Sabatos-Peyton CA, et al. Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nat Commun. 2014 Jan;5:4741. pmid:25182274
- 3. Erickson JJ, Rogers MC, Tollefson SJ, Boyd KL, Williams J V. Multiple Inhibitory Pathways Contribute to Lung CD8+ T Cell Impairment and Protect against Immunopathology during Acute Viral Respiratory Infection. J Immunol. 2016 Jun 3;197(1):233–43. pmid:27259857
- 4. Kadowaki A, Miyake S, Saga R, Chiba A, Mochizuki H, Yamamura T. Gut environment-induced intraepithelial autoreactive CD4(+) T cells suppress central nervous system autoimmunity via LAG-3. Nat Commun. 2016 May 20;7:11639. pmid:27198196
- 5. Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Współczesna Onkol. 2018 Mar;2018(1):61–7.
- 6. NobelPrize.org. Press Release [Internet]. Nobel Media AB. 2018. Available from: https://www.nobelprize.org/prizes/medicine/2018/press-release/. [cited 2018 Nov 26].
- 7. Maçon-Lemaître L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology. 2005 Jun 1;115(2):170–8. pmid:15885122
- 8. Bae J, Lee SJ, Park C-G, Lee YS, Chun T. Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling. J Immunol. 2014 Sep 15;193(6):3101–12. pmid:25108024
- 9. Woo S-R, Li N, Bruno TC, Forbes K, Brown S, Workman C, et al. Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4. Eur J Immunol. 2010 Jun;40(6):1768–77. pmid:20391435
- 10. Yamamoto T, Price DA, Casazza JP, Ferrari G, Nason M, Chattopadhyay PK, et al. Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. Blood. 2011 May 5;117(18):4805–15. pmid:21398582
- 11. Tian X, Zhang A, Qiu C, Wang W, Yang Y, Qiu C, et al. The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects. J Immunol. 2015 Mar 16;194(8):3873–82. pmid:25780040
- 12. Fromentin R, Bakeman W, Lawani MB, Khoury G, Hartogensis W, DaFonseca S, et al. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathog. 2016 Jul 14;12(7):e1005761. pmid:27415008
- 13. Wherry EJ, Ha S-J, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection. Immunity. 2007;27(4):670–84. pmid:17950003
- 14. Cook KD, Whitmire JK. LAG-3 Confers a Competitive Disadvantage upon Antiviral CD8+ T Cell Responses. J Immunol. 2016 Jul 1;197(1):119–27. pmid:27206765
- 15. Juno JA, Stalker AT, Waruk JL, Oyugi J, Kimani M, Plummer FA, et al. Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment. Retrovirology. 2015 Feb 13;12(1):17.
- 16. Taborda NA, Hernández JC, Lajoie J, Juno JA, Kimani J, Rugeles MT, et al. Short Communication: Low Expression of Activation and Inhibitory Molecules on NK Cells and CD4(+) T Cells Is Associated with Viral Control. AIDS Res Hum Retroviruses. 2015 Jun;31(6):636–40. pmid:25738606
- 17. Camisaschi C, De Filippo A, Beretta V, Vergani B, Villa A, Vergani E, et al. Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. J Invest Dermatol. 2014 Jul;134(7):1893–902. pmid:24441096
- 18. Phillips BL, Mehra S, Ahsan MH, Selman M, Khader SA, Kaushal D, et al. LAG3 Expression in Active Mycobacterium tuberculosis Infections the Training in Lung Molecular and Cell. Am J Pathol. 2015;185:820–33. pmid:25549835
- 19. Hoffmann M, Pantazis N, Martin GE, Hickling S, Hurst J, Meyerowitz J, et al. Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection. PLoS Pathog. 2016 Jul 14;12(7):e1005661. pmid:27415828
- 20. Kroy DC, Ciuffreda D, Cooperrider JH, Tomlinson M, Hauck GD, Aneja J, et al. Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology. 2014 Feb 1;146(2):550–61. pmid:24148617
- 21. Ye B, Li X, Dong Y, Wang Y, Tian L, Lin S, et al. Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis B: A balance between immunity strength and liver injury extent. Medicine (Baltimore). 2017 Jan;96(1):e5275.
- 22. Chen N, Liu Y, Guo Y, Chen Y, Liu X, Liu M. LAG-3 negatively regulates the function of intrahepatic HCV-specific CD8(+) T cells. J Gastroenterol Hepatol. 2015 Dec;30(12):1788–95. pmid:26095288
- 23. Annunziato F, Manetti R, Cosmi L, Galli G, Heusser CH, Romagnani S, et al. Opposite role for interleukin-4 and interferon-γ on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells. Eur J Immunol. 1997 Sep 1;27(9):2239–44. pmid:9341765
- 24. Bruniquel D, Borie N, Hannier S, Triebel F. Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II. Immunogenetics. 1998 Jul;48(2):116–24. pmid:9634475
- 25. Sun H, Sun C, Xiao W. Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations. Cytokine. 2014;65:33–41. pmid:24139237
- 26. Okamura T, Fujio K, Shibuya M, Sumitomo S, Shoda H, Sakaguchi S, et al. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc Natl Acad Sci. 2009 Aug 18;106(33):13974–9. pmid:19666526
- 27. Iwasaki Y, Fujio K, Okamura T, Yanai A, Sumitomo S, Shoda H, et al. Egr-2 transcription factor is required for Blimp-1-mediated IL-10 production in IL-27-stimulated CD4 + T cells. Eur J Immunol. 2013 Apr 1;43(4):1063–73. pmid:23349024
- 28. Kao C, Oestreich KJ, Paley MA, Crawford A, Angelosanto JM, Ali M-AA, et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Immunol. 2011 May 29;12(7):663–71. pmid:21623380
- 29. Durham NM, Nirschl CJ, Jackson CM, Elias J, Kochel CM, Anders RA, et al. Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS ONE. 2014 Jan;9(11):e109080. pmid:25372844
- 30. Buggert M, Tauriainen J, Yamamoto T, Frederiksen J, Ivarsson MA, Michaëlsson J, et al. T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection. Luban J, editor. Pathog PLoS. 2014 Jul 17;10(7):e1004251.
- 31. Grosso JF, Goldberg M V, Getnet D, Bruno TC, Yen H-R, Pyle KJ, et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol. 2009 Jun 1;182(11):6659–69. pmid:19454660
- 32. Li N, Wang Y, Forbes K, Vignali KM, Heale BS, Saftig P, et al. Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J. 2007 Jan 24;26(2):494–504. pmid:17245433
- 33. Chodisetti SB, Gowthaman U, Rai PK, Vidyarthi A, Khan N, Agrewala JN. Triggering Through Toll-like Receptor 2 Limits Chronically Stimulated T-helper Type 1 Cells From Undergoing Exhaustion. J Infect Dis. 2015 Feb 1;211(3):486–96. pmid:25156558
- 34. Velu V, Shetty RD, Larsson M, Shankar EM. Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology. 2015 Jan;12:14. pmid:25756928
- 35. Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990 May 1;171(5):1393–405. pmid:1692078
- 36. Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, El-Tayar N, et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Immunology. 1997 May 27;94(11):5744–9.
- 37. Baixeras E, Huard B, Miossec C, Jitsukawa S, Martin M, Hercend T, et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med. 1992 Aug 1;176(2):327–37. pmid:1380059
- 38. Huard B, Prigent P, Tournier M, Bruniquel D, Triebel F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol. 1995 Sep;25(9):2718–21. pmid:7589152
- 39. Xu F, Liu J, Liu D, Liu B, Wang M, Hu Z, et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res. 2014 Jul 1;74(13):3418–28. pmid:24769443
- 40. Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong TD, et al. Galectin-3 shapes anti-tumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res. 2015 Feb 17;3(4):412–23. pmid:25691328
- 41. Fogel S, Guittaut M, Legrand A, Monsigny M, Hébert E. The tat protein of HIV-1 induces galectin-3 expression. Glycobiology. 1999 Apr;9(4):383–7. pmid:10089212
- 42. Wang S-F, Tsao C-H, Lin Y-T, Hsu DK, Chiang M-L, Lo C-H, et al. Galectin-3 promotes HIV-1 budding via association with Alix and Gag p6. Glycobiology. 2014 Nov;24(11):1022–35. pmid:24996823
- 43. Sciacchitano S, Lavra L, Morgante A, Ulivieri A, Magi F, De Francesco G, et al. Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. Int J Mol Sci. 2018 Jan 26;19(2):379.
- 44. Dominguez-Soto A, Aragoneses-Fenoll L, Martin-Gayo E, Martinez-Prats L, Colmenares M, Naranjo-Gomez M, et al. The DC-SIGN-related lectin LSECtin mediates antigen capture and pathogen binding by human myeloid cells. Blood. 2007 Jun 15;109(12):5337–45. pmid:17339424
- 45. Yokosuka T, Kobayashi W, Takamatsu M, Sakata-Sogawa K, Zeng H, Hashimoto-Tane A, et al. Spatiotemporal Basis of CTLA-4 Costimulatory Molecule-Mediated Negative Regulation of T Cell Activation. Immunity. 2010 Sep 24;33(3):326–39. pmid:20870175
- 46. Workman CJ, Dugger KJ, Vignali DAA. Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-3. J Immunol. 2002 Nov 15;169(10):5392–5. pmid:12421911
- 47. Bhagwat B, Cherwinski H, Sathe M, Seghezzi W, McClanahan TK, de Waal Malefyt R, et al. Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction. J Immunol Methods. 2018 Feb 7;456:7–14. pmid:29427592
- 48. Hannier S, Tournier M, Bismuth G, Triebel F. CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J Immunol. 1998 Oct 15;161(8):4058–65. pmid:9780176
- 49. Iouzalen N, Andreae S, Hannier S, Triebel F. LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway. Eur J Immunol. 2001 Oct;31(10):2885–91. pmid:11592063
- 50. Workman CJ, Rice DS, Dugger KJ, Kurschner C, Vignali DAA. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol. 2002 Aug;32(8):2255–63. pmid:12209638
- 51. Crawford A, Angelosanto JM, Kao C, Doering TA, Odorizzi PM, Barnett BE, et al. Molecular and transcriptional basis of CD4+ T cell dysfunction during chronic infection. Immunity. 2014 Feb 20;40(2):289–302. pmid:24530057
- 52. Huard B, Tournier M, Hercend T, Triebel F, Faure F. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur J Immunol. 1994 Dec;24(12):3216–21. pmid:7805750
- 53. Sega EI, Leveson-Gower DB, Florek M, Schneidawind D, Luong RH, Negrin RS. Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PLoS ONE. 2014 Jan 27;9(1):e86551. pmid:24475140
- 54. Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest. 2007 Nov 1;117(11):3383–92. pmid:17932562
- 55. Workman CJ, Vignali DAA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol. 2003 Apr;33(4):970–9. pmid:12672063
- 56. Hasenkrug KJ, Chougnet CA, Dittmer U. Regulatory T cells in retroviral infections. Hobman TC, editor. Pathog PLoS. 2018 Feb 15;14(2):e1006776.
- 57. Chevalier MF, Weiss L. The split personality of regulatory T cells in HIV infection. Blood. 2013 Jan 3;121(1):29–37. pmid:23043072
- 58. Kleinman AJ, Sivanandham R, Pandrea I, Chougnet CA, Apetrei C. Regulatory T Cells As Potential Targets for HIV Cure Research. Front Immunol. 2018 Apr 13;9:734. pmid:29706961
- 59. Huang C-T, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004 Oct;21(4):503–13. pmid:15485628
- 60. Bayry J, Triebel F, Kaveri S V., Tough DF. Human Dendritic Cells Acquire a Semimature Phenotype and Lymph Node Homing Potential through Interaction with CD4+CD25+ Regulatory T Cells. J Immunol. 2007 Apr 1;178(7):4184–93. pmid:17371975
- 61. Camisaschi C, Casati C, Rini F, Perego M, De Filippo A, Triebel F, et al. LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites. J Immunol. 2010 Jun 1;184(11):6545–51. pmid:20421648
- 62. Zhang Q, Chikina M, Szymczak-Workman AL, Horne W, Kolls JK, Vignali KM, et al. LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes. Sci Immunol. 2017 Mar 31;2(9).
- 63. Xia J, Ni Z, Wang J, Zhu S, Ye H. Overexpression of Lymphocyte Activation Gene-3 Inhibits Regulatory T Cell Responses in Osteoarthritis. DNA Cell Biol. 2017 Oct;36(10):862–9. pmid:28800255
- 64. Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, et al. Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II. J Immunol. 2008 Apr 18;180(9):5916–26. pmid:18424711
- 65. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev. 2010 Mar;234(1):142–62. pmid:20193017
- 66. Workman CJ, Wang Y, El Kasmi KC, Pardoll DM, Murray PJ, Drake CG, et al. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol. 2009 Feb 15;182(4):1885–91. pmid:19201841
- 67. Workman CJ, Vignali DAA. Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223). J Immunol. 2005 Jan 5;174(2):688–95. pmid:15634887
- 68. Jiang J, Wang X, An H, Yang B, Cao Z, Liu Y, et al. MAIT Cell Function is Modulated by PD-1 Signaling in Patients with Active Tuberculosis. Am J Respir Crit Care Med. 2014 Jun 30;140630082918004.
- 69. Miyazaki T, Dierich A, Benoist C, Mathis D. Independent modes of natural killing distinguished in mice lacking Lag3. Science. 1996 Apr 19;272(5260):405–8. pmid:8602528
- 70. Huard B, Tournier M, Triebel F. LAG-3 does not define a specific mode of natural killing in human. Immunol Lett. 1998 Apr;61(2–3):109–12. pmid:9657262
- 71. Ohs I, Ducimetière L, Marinho J, Kulig P, Becher B, Tugues S. Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade. Cancer Res. 2017 Oct 17;77(24):7059–71. pmid:29042417
- 72. Liew PX, Lee W-Y, Kubes P. iNKT Cells Orchestrate a Switch from Inflammation to Resolution of Sterile Liver Injury. Immunity. 2017 Oct 17;47(4):752–765.e5. pmid:29045904
- 73. Juno JA, Keynan Y, Fowke KR. Invariant NKT cells: regulation and function during viral infection. PLoS Pathog. 2012;8(8):e1002838. pmid:22916008
- 74. Byun H-J, Jung W-W, Lee D-S, Kim S, Kim SJ, Park C-G, et al. Proliferation of activated CD1d-restricted NKT cells is down-modulated by lymphocyte activation gene-3 signaling via cell cycle arrest in S phase. Cell Biol Int. 2007 Mar;31(3):257–62. pmid:17175182
- 75. Saeidi A, Ellegård R, Yong YK, Tan HY, Velu V, Ussher JE, et al. Functional role of mucosal-associated invariant T cells in HIV infection. J Leukoc Biol. 2016 Aug 1;100(2):305–14. pmid:27256572
- 76. Shaler CR, Choi J, Rudak PT, Memarnejadian A, Szabo PA, Tun-Abraham ME, et al. MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: Defining a novel mechanism of superantigen-induced immunopatho. Bhandoola A, editor. PLoS Biol. 2017 Jun 20;15(6):e2001930. pmid:28632753
- 77. Rockstroh JK, Mohr R, Behrens G, Spengler U. Liver fibrosis in HIV. Curr Opin HIV AIDS. 2014 Jul;9(4):365–70. pmid:24840057
- 78. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology. 2006 Feb;43(2 Suppl 1):S54–62.
- 79. Kurioka A, Walker LJ, Klenerman P, Willberg CB. MAIT cells: new guardians of the liver. Clin Transl Immunol. 2016 Aug;5(8):e98.
- 80. Liu W, Tang L, Zhang G, Wei H, Cui Y, Guo L, et al. Characterization of a novel C-type lectin-like gene, LSECtin: demonstration of carbohydrate binding and expression in sinusoidal endothelial cells of liver and lymph node. J Biol Chem. 2004 Apr 30;279(18):18748–58. pmid:14711836
- 81. Poccia F, Boullier S, Lecoeur H, Cochet M, Poquet Y, Colizzi V, et al. Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J Immunol. 1996 Jul 1;157(1):449–61. pmid:8683151
- 82. Gogoi D, Biswas D, Borkakoty B, Mahanta J. Exposure to Plasmodium vivax is associated with the increased expression of exhaustion markers on γδ T lymphocytes. Parasite Immunol. 2018 Oct 1;e12594. pmid:30276843
- 83. Hurst J, Hoffmann M, Pace M, Williams JP, Thornhill J, Hamlyn E, et al. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat Commun. 2015 Jan 9;6:8495.
- 84. Rotger M, Dalmau J, Rauch A, McLaren P, Bosinger SE, Martinez R, et al. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest. 2011 Jun 1;121(6):2391–400. pmid:21555857
- 85. Nunnari G, Fagone P, Condorelli F, Nicoletti F, Malaguarnera L, Di Rosa M. CD4+ T-cell gene expression of healthy donors, HIV-1 and elite controllers: Immunological chaos. Cytokine. 2016 Apr 21;83:127–35. pmid:27108398
- 86. ROMANCHIKOVA N, Ivanova V, Scheller C, Jankevics E, Jassoy C, Serfling E. NFAT transcription factors control HIV-1 expression through a binding site downstream of TAR region. Immunobiology. 2003;208(4):361–5. pmid:14748509
- 87. DaFonseca S, Chomont N, El Far M, Boulassel R, Routy J, Sékaly R. Purging the HIV-1 reservoir through the disruption of the PD-1 pathway. J Int AIDS Soc. 2010;13(Suppl 3):O15.
- 88. Van der Sluis RM, Kumar NA, Evans VA, Dantanarayana AI, Sekaly RP, Fromentin R, et al. Anti-PD-1 disrupts HIV latency in non-proliferating but not in proliferating T cells. J Virus Erad. 2017;3(1).
- 89. Evans VA, Van Der Sluis RM, Solomon A, Dantanarayana A, McNeil C, Garsia R, et al. PD-1 contributes to the establishment and maintenance of HIV-1 latency. AIDS. 2018 May 9;1.
- 90. Mylvaganam GH, Chea LS, Tharp GK, Hicks S, Velu V, Iyer SS, et al. Combination anti–PD-1 and antiretroviral therapy provides therapeutic benefit against SIV. JCI Insight. 2018 Sep 20;3(18).
- 91. Fromentin R, Pardons M, Deeks SG, Lewin SR, Routy J-P, Sekaly RP, et al. PD-1 engagement potently inhibits HIV reactivation from latency. In: HIV and Co-Infections: Pathogenesis, Inflammation and Persistence. Whistler: Keystone Symposia; 2018.
- 92. Cartwright EK, Spicer L, Smith SA, Lee D, Fast R, Paganini S, et al. CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy. Immunity. 2016 Sep 20;45(3):656–68. pmid:27653601
- 93. Workman CJ, Cauley LS, Kim I-J, Blackman MA, Woodland DL, Vignali DAA. Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation In Vivo. J Immunol. 2004 Apr 20;172(9):5450–5. pmid:15100286
- 94. Porichis F, Kwon DS, Zupkosky J, Tighe DP, McMullen A, Brockman MA, et al. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood. 2011 Jul 28;118(4):965–74. pmid:21652684
- 95. Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15016–21. pmid:18809920
- 96. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009 Mar 12;458(7235):206–10. pmid:19078956
- 97. Seung E, Dudek TE, Allen TM, Freeman GJ, Luster AD, Tager AM. PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. PLoS ONE. 2013 Jan;8(10):e77780. pmid:24204962
- 98. Guihot A, Marcelin A-G, Massiani M-A, Samri A, Soulié C, Autran B, et al. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Ann Oncol. 2018 Feb 1;29(2):517–8. pmid:29206889
- 99. Wightman F, Solomon A, Kumar SS, Urriola N, Gallagher K, Hiener B, et al. Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. AIDS. 2015 Feb 20;29(4):504–6. pmid:25628259
- 100. Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, et al. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. J Infect Dis. 2017 Jun 1;215(11):1725–33. pmid:28431010
- 101. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001 Jan 12;291(5502):319–22. pmid:11209085
- 102. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999 Aug;11(2):141–51. pmid:10485649
- 103. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995 Nov 10;270(5238):985–8. pmid:7481803
- 104. Ascierto PA, Melero I, Bhatia S, Bono P, Sanborn RE, Lipson EJ. Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. J Clin Oncol. 2017;35(15):9520.
- 105. Huang R-Y, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017 Jan 2;6(1):e1249561. pmid:28197366
- 106. Stecher C, Battin C, Leitner J, Zettl M, Grabmeier-Pfistershammer K, Höller C, et al. PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells. Front Immunol. 2017;8:572. pmid:28588576
- 107. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009 Jan;10(1):29–37. pmid:19043418
- 108. Foy SP, Sennino B, Dela Cruz T, Cote JJ, Gordon EJ, Kemp F, et al. Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice. PLoS ONE. 2016 Jan;11(2):e0150084. pmid:26910562
- 109. Hannier S. The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes. Int Immunol. 1999 Nov 1;11(11):1745–52. pmid:10545478
- 110. Siebert N, Zumpe M, Jüttner M, Troschke-Meurer S, Lode HN. PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO. Oncoimmunology. 2017;6(10):e1343775. pmid:29123953